SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Alper H.YUKSEL who wrote (12014)12/3/1997 2:55:00 PM
From: Andrew H  Respond to of 32384
 
>>I only know about LLY's halting their collaboration with SMTG, on the work for a blood substitute. Are there others as well ?<<

There are others. Just read yesterday on the AGPH thread that LLY pulled out on the development of Viracept. Huge mistake. However, they are looking to replace sales for Prozac when it goes off patent, so they may be less likely to drop Targretin and LGND's diabetes lineup.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News